CAN
SPRO icon

Cetera Advisor Networks’s Spero Therapeutics SPRO Stock Holding History

Cetera Advisor Networks’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-900
Closed -$12K – 2779
2020
Q2 		$12K Buy
+900
New +$10.1K ﹤0.01% 2650

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Cetera Advisor Networks's SPRO Position: Q3 2020 in Review

Cetera Advisor Networks sold out of Spero Therapeutics (SPRO) in Q3 2020, closing a stake of 900 shares — an estimated $12K sold.

Cetera Advisor Networks first reported a position in SPRO in Q2 2020 and held it in 1 quarter. The position peaked at $12K in Q2 2020. 78 funds tracked by Wall St. Rank hold SPRO as of Q3 2020.

  • Cetera Advisor Networks reported no remaining Spero Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Cetera Advisor Networks sold 900 Spero Therapeutics shares in Q3 2020, an estimated $12K.
  • Cetera Advisor Networks first reported a position in Spero Therapeutics in Q2 2020 and held it in 1 quarter.
  • Cetera Advisor Networks's Spero Therapeutics position peaked at $12K in Q2 2020.
  • 78 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2020.

Based on Cetera Advisor Networks's 13F filing for Q3 2020, filed 13 Nov 2020.